| 产品编号 | bs-1489R-PE-Cy7 |
| 英文名称 | Anti-BIRC6/PE-Cy7 |
| 中文名称 | PE-Cy7标记的Apollon凋亡抑制蛋白抗体 |
| 别 名 | BIRC6; Apollon; Apollon protein; Baculoviral IAP repeat containing 6; Baculoviral IAP repeat containing protein 6; BIRC 6; BRUCE; FLJ13726; FLJ13786; KIAA1289; Ubiquitin conjugating BIR domain enzyme apollon; BIRC6_HUMAN. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 肿瘤 细胞生物 细胞凋亡 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | (predicted: Human, Mouse, Rat, Pig, Cow, Horse, Rabbit, ) |
| 产品应用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 530kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Apollon C terminus |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 |
background: Conserved genes that encode inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in human cancers and are associated with resistance to therapy. IAPs contain a 70 amino acid cysteine and histidine rich baculovirus IAP repeat (BIR) and often a zinc binding RING finger. Chen et al. (1999) found that some brain cancer cell lines with high expression of BIRC6 exhibited resistance to apoptosis in the presence of anticancer drugs. Treatment of a high expressing cell line with BIRC6 antisense oligonucleotides reduced BIRC6 expression and reversed the resistance to anticancer drugs. Function: Anti-apoptotic protein which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Has an unusual ubiquitin conjugation system in that it could combine in a single polypeptide, ubiquitin conjugating (E2) with ubiquitin ligase (E3) activity, forming a chimeric E2/E3 ubiquitin ligase. Its tragets include CASP9 and DIABLO/SMAC. Acts as an inhibitor of CASP3, CASP7 and CASP9. Important regulator for the final stages of cytokinesis. Crucial for normal vesicle targeting to the site of abscission, but also for the integrity of the midbody and the midbody ring, and its striking ubiquitin modification. Subunit: Homodimer. Binds the activated, processed forms of CASP3, CASP6, CASP7 and CASP9. Interacts with RNF41, DIABLO/SMAC, HTRA2, KIF23/MKLP1, USP8/UBPY, BIRC5/survivin, MAP2K1/MEK1, RAB8A/RAB8, RAB11A/RAB11, PLK1, EXOC3/SEC6 and EXOC4/SEC8. Subcellular Location: Golgi apparatus, trans-Golgi network membrane. Midbody. Endosome. Cytoplasm, cytoskeleton, spindle pole. Cytoplasm, cytoskeleton, centrosome. Note=Concentrates in a pericentriolar compartment in interphase, moves partially to spindle poles in metaphase, and finally localizes to the spindle midzone and the midbody in telophase and during cytokinesis. Tissue Specificity: Expressed in brain cancer cells. Post-translational modifications: Ubiquitinated. Ubiquitination is mediated by the RNF41 E3 ligase and leads to proteasomal degradation, impairing inhibition of apoptosis. Deubiquitinated by USP8/UBPY. Similarity: In the C-terminal section; belongs to the ubiquitin-conjugating enzyme family. Contains 1 BIR repeat. Database links: Entrez Gene: 57448 Human Entrez Gene: 12211 Mouse Omim: 605638 Human SwissProt: Q9NR09 Human SwissProt: O88738 Mouse Unigene: 150107 Human Unigene: 290908 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Apollon是凋亡抑制蛋白家族IAP(inhibitors of apoptosis protein 凋亡抑制因子)的成员之一，它通过抑制Smac和caspase-9酶活性而产生抗凋亡作用它是IAP家族中分子量最大的成员,Apollon在某些肿瘤组织中表达。 |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
